SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Imclone systems (IMCL)
IMCL 0.1590.0%Oct 5 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JEB who wrote (201)1/11/1999 5:01:00 PM
From: QuietWon  Read Replies (2) of 2515
 
This should be very explanatory- diff btween IMCL and Entremed - Entremed couldn't reproduce it's results; IMCL has ! In phase II of C225, all but 1 or 2 patients had 100% shrinkage of tumor ! Entremed couldn't reproduce.

Now, IMCL has given those results with it's "business plan" for testing Phase III and waiting for FDA go-ahead to enter Phase III.

Phase II tells you if it works, and III is a larger scale. BEING PERMITTED TO ENTER PHASE III is the CRUCIAL PT with any drug and remember 50% of stock's gains come from Phase III until Marketing phase.

I believe this one's a winner!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News